Skip to main content
. 2021 May 25;1(6):865–878. doi: 10.1021/jacsau.1c00078

Figure 4.

Figure 4

Isobolographic analysis of the antiproliferative activity of the 1:1 and 1:2 [Ti(Def)2]2–/cisplatin combinations against Jurkat cells for 48 h.